Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its price objective lowered by Royal Bank Of Canada from $21.00 to $18.00 in a research note issued on Friday. The brokerage currently has a “sector perform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 48.39% from the stock’s current price.

VRX has been the topic of a number of other reports. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a report on Sunday, July 30th. BidaskClub upgraded Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Vetr raised Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $13.68 target price for the company in a research report on Friday, October 6th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a research report on Monday, October 9th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 target price on shares of Valeant Pharmaceuticals International in a research report on Friday, June 30th. Five research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $17.56.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 12.13 on Friday. The stock’s market capitalization is $4.23 billion. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $24.30. The stock has a 50 day moving average price of $13.81 and a 200 day moving average price of $13.59.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. The business had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.88) EPS. On average, analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/22/valeant-pharmaceuticals-international-inc-vrx-pt-lowered-to-18-00.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were acquired at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.87% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Valeant Pharmaceuticals International by 2.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock worth $8,509,000 after purchasing an additional 13,810 shares during the period. Morgan Stanley increased its stake in shares of Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock worth $30,631,000 after purchasing an additional 903,256 shares during the period. Legal & General Group Plc increased its stake in shares of Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock worth $23,895,000 after purchasing an additional 121,032 shares during the period. Paloma Partners Management Co increased its stake in shares of Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock worth $310,000 after purchasing an additional 2,996 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after purchasing an additional 621,618 shares during the period. Institutional investors and hedge funds own 50.44% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.